Cabozantinib in Men With Castration-Resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01703065
Recruitment Status : Terminated (Closed 2017 for low accrual. Last data for primary outcome on 02Feb2015.)
First Posted : October 10, 2012
Last Update Posted : December 5, 2017
Prostate Cancer Foundation
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Celestia Higano, University of Washington

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Terminated
  Actual Primary Completion Date : February 2, 2015
  Actual Study Completion Date : September 18, 2015
  Certification/Extension First Submitted : October 16, 2017

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 August 3, 2018
August 31, 2018
2 November 6, 2018